Veru to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
January 31 2024 - 8:30AM
Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical
company focused on developing novel medicines for obesity,
oncology, and viral induced acute respiratory distress syndrome
(ARDS), today announced that Mitchell Steiner, M.D., Chairman,
President and Chief Executive Officer of Veru, will present an
update of Veru’s Phase 2b clinical program of enobosarm to augment
fat loss and to avoid muscle loss when combined with GLP-1 drugs
for weight loss at the upcoming virtual Oppenheimer 34th Annual
Healthcare Life Sciences Conference on Wednesday, February 14, 2024
at 12:40 pm – 1:10 pm ET.
A live webcast will be accessible through the Investors section
of the Company’s website at www.verupharma.com. Following the
event, an archived webcast will be available on the Veru
website.
About Veru Inc.Veru is a late clinical stage
biopharmaceutical company focused on developing novel medicines for
the treatment of metabolic diseases, oncology, and ARDS. The
Company’s drug development program includes two late-stage novel
small molecules, enobosarm and sabizabulin.
Metabolic pipeline: Enobosarm (aka ostarine, MK-2866, GTx-024,
S-22, and VERU-024), an oral selective androgen receptor modulator
(SARM), is being developed as a treatment in combination with
weight loss drugs to augment fat loss and to avoid muscle loss in
overweight or obese patients for chronic weight management.
Initially, enobosarm will be developed in a Phase 2b clinical study
to address the large subpopulation of sarcopenic obese or
overweight elderly patients receiving a GLP-1 RA who are at-risk
for developing muscle atrophy and muscle weakness leading to
physical function mobility disability and frailty.
Oncology pipeline: Phase 3 clinical development of enobosarm for
treatment of androgen receptor positive (AR+), estrogen receptor
positive (ER+) and human epidermal growth factor receptor 2
negative (HER2-) metastatic breast cancer in the 2nd line
setting.
Infectious disease pipeline: sabizabulin, a microtubule
disruptor, is being developed as a Phase 3 clinical trial for the
treatment of hospitalized patients with viral-induced ARDS. The
Company does not intend to undertake further development of
sabizabulin for the treatment of viral-induced ARDS until we obtain
funding from government grants, pharmaceutical company
partnerships, or other similar third-party external sources.
The Company also has an FDA-approved commercial product, the FC2
Female Condom® (Internal Condom), for the dual protection against
unplanned pregnancy and sexually transmitted infections.
Forward-Looking StatementsThis press release
contains "forward-looking statements" as that term is defined in
the Private Securities Litigation Reform Act of 1995, including,
without limitation, express or implied statements related to Veru’s
expectations regarding whether the FDA will accept the enobosarm
IND, whether and when the planned phase 2b trial of enobosarm
discussed above will commence, the planned design, timing,
endpoints, patient population and patient size of such trial and
whether such trial will successfully meet any of its endpoints,
whether enobosarm will meet any unmet need for obesity patients,
whether the Company’s oncology development program will be
successful and whether the Company will obtain the resources
necessary to develop its infectious disease program and whether the
Company will be successful in its transformation into a late stage
biopharmaceutical company focused on obesity and oncology. The
words "anticipate," "believe," "could," "expect," "intend," "may,"
"opportunity," "plan," "predict," "potential," "estimate,"
"should," "will," "would" and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Any
forward-looking statements in this press release are based upon
current plans and strategies of Veru Inc. (the Company) and reflect
the Company's current assessment of the risks and uncertainties
related to its business and are made as of the date of this press
release. The Company assumes no obligation to update any
forward-looking statements contained in this press release because
of new information or future events, developments or circumstances.
Such forward-looking statements are subject to known and unknown
risks, uncertainties and assumptions, and if any such risks or
uncertainties materialize or if any of the assumptions prove
incorrect, our actual results could differ materially from those
expressed or implied by such statements. Factors that may cause
actual results to differ materially from those contemplated by such
forward-looking statements include, but are not limited to,
uncertainties related to market conditions and the satisfaction of
customary closing conditions related to the proposed public
offering and the Company’s expectations regarding the completion,
timing and size of the proposed public offering and the use of
proceeds therefrom. This list is not exhaustive and other risks are
detailed in the Company’s periodic reports filed with the SEC,
including the Company's Form 10-K for the year ended September 30,
2023.
Investor and Media Contact:Samuel FischExecutive Director,
Investor Relations and Corporate CommunicationsEmail:
veruinvestor@verupharma.com
Veru (NASDAQ:VERU)
Historical Stock Chart
From Mar 2024 to Apr 2024
Veru (NASDAQ:VERU)
Historical Stock Chart
From Apr 2023 to Apr 2024